Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

Abstract Background In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed multiple myeloma. Per protocol, patients received KRd for a maximum of 18 c...

Full description

Bibliographic Details
Main Authors: Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel, Philippe Moreau
Format: Article
Language:English
Published: BMC 2018-04-01
Series:Journal of Hematology & Oncology
Subjects:
Clinical research
Clinical trials
Multiple myeloma
Myeloma therapy
Online Access:http://link.springer.com/article/10.1186/s13045-018-0583-7

Internet

http://link.springer.com/article/10.1186/s13045-018-0583-7

Similar Items